|Articles|February 15, 2002
Allergan spin-off places focus on pharmaceuticals New entity formed for optical medical devices
Irvine, CA-Allergan Inc. is separating the pharmaceutical and optical medical device segments of its business in a move aimed at placing the company as the number one player in both arenas.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
Opus Genetics reaches FDA alignment on phase 3 registrational design for OPGx-LCA5 gene therapy
3
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
4
Port Delivery System Therapies in Retinal Vascular Diseases
5


















